Lack of data leads to double NICE no for Novartis's Glivec
This article was originally published in Scrip
NICE, the National Institute for health and Clinical Excellence in the UK, is set to decline NHS funding for high doses of Novartis's Glivec (imatinib) for treating unresectable and or metastatic gastrointestinal stromal tumors (GIST), it says in preliminary draft guidance published today. It based the decision on a lack of "good quality clinical and cost-effectiveness data".
You may also be interested in...
Biogen has described as “exciting” a first-of-a-kind interim data review that has led to expanded recommendations for the company’s spinal muscular atrophy drug Spinraza.
Artificial intelligence can facilitate outcomes agreements and help companies make their value proposition to health technology assessment bodies.
After arbitrators set an unpalatably low price for the company, bluebird is withdrawing its Zyntgelo gene therapy from Germany. The company also announced it would be restructuring its workforce, with job losses expected.